| 查看: 303 | 回复: 2 | |||
madai26银虫 (小有名气)
|
[交流]
【求助】有没有虫子帮我查一下fasidotril这个药在国外有没有上市? 已有2人参与
|
|
因为我们单位没啥数据库,所以查不到。 fasidotril 法西多曲 ACE/NEP双向抑制剂 临床试验做到3期,但后来就没下文了,哪位好心的虫子帮个忙呢?帮我把它有没有上市,在哪上市的查一下? |
» 猜你喜欢
国家高层次人才李兴淑教授课题组招收博士研究生
已经有39人回复
己酮可可碱过氧化杂质限度
已经有2人回复
药理学论文润色/翻译怎么收费?
已经有240人回复
求助Isoeugenol质量标准
已经有0人回复
Gliclazide
已经有0人回复
塞替派/噻替哌(Thiotepa) 质量控制
已经有16人回复
有没有大佬可以帮忙查下Trijardy XR和Qternmet XR历年销售数据呀
已经有0人回复
酰胺水解求助
已经有11人回复
中药材标准目录大全llp2026(含各省市中药材和炮制规范)
已经有0人回复
酰胺脱乙酰基
已经有12人回复
nkbeholder
木虫 (正式写手)
- DRDEPI: 1
- 应助: 11 (小学生)
- 金币: 2945.1
- 散金: 4
- 红花: 5
- 帖子: 748
- 在线: 303.7小时
- 虫号: 202353
- 注册: 2006-03-01
- 性别: GG
- 专业: 药物化学
★ ★
madai26(金币+2):谢谢参与
warlen(金币+1):谢谢参与 2010-08-04 15:15:09
madai26(金币+2):谢谢参与
warlen(金币+1):谢谢参与 2010-08-04 15:15:09
|
这上面写到2期就中止了。 Originator Company: Bioprojet (France) Parent Company: Bioprojet Licensee: Eli Lilly Highest Phase: Discontinued II Development Status: Discontinued II, France, Congestive heart failure Discontinued II, France, Hypertension Discontinued Preclinical, France, Postmyocardial infarction Introduction: Fasidotril, the prodrug of its active metabolite fasidoprilat, is a mixed inhibitor of ACE and neutral endopeptidase. It was undergoing phase II development with Bioprojet in France for the treatment of congestive heart failure and hypertension. It was also in preclinical development for postmyocardial infarction. However, development appears to have been discontinued. In October 2001, Bioprojet and Eli Lilly announced a development and commercialisation collaboration. Under the terms of the agreement, Lilly received exclusive worldwide commercialisation rights excluding Japan and certain countries in Europe. Lilly was to continue to develop fasidotril through to registration, and was to manufacture the finished product; Bioprojet was to manufacture the bulk material. |
2楼2010-08-04 14:45:13
mrzouhao
木虫之王 (文坛精英)
- DRDEPI: 1
- 应助: 179 (高中生)
- 贵宾: 0.108
- 金币: 99904.9
- 散金: 11601
- 红花: 134
- 沙发: 22
- 帖子: 46580
- 在线: 4386.8小时
- 虫号: 201350
- 注册: 2006-02-28
- 专业: 药剂学
3楼2010-08-04 15:13:10













回复此楼